Latest Content

Dr. Gwen Nichols explains how Orca‑T may reduce graft-versus-host disease and impact treatment decisions for certain patients with blood cancers.

ACS data show rising five-year survival and shifting cancer care toward survivorship, access to novel therapies and prevention as incidence climbs.

Study finds similar PFS across races in ovarian cancer trials, but Black patients had shorter OS, raising concerns about disparities after trial completion.

For many patients with cancer, it is never too soon to begin discussing fertility preservation options as they begin their cancer journeys.

A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients live longer after cancer

After cancer, I learned how to weigh environmental risks and make informed decisions for long-term survivorship and peace of mind.

FDA grants breakthrough status to Rybrevant Faspro for recurrent or metastatic HPV-negative head and neck cancer after prior therapy.

Annamycin plus cytarabine achieved a 40% preliminary remission rate in relapsed AML, including patients who previously received Venclexta-based therapy.

Researchers developed a tool to predict chemotherapy response for patients with triple-negative breast cancer.

Dr. Ashkan Emadi outlines eligibility, referral and care logistics for a first-in-world subcutaneous Blincyto trial at WVU Cancer Institute.

A new study suggests that a proactive, tech-driven approach to palliative care can significantly improve the lives of children with advanced cancer.

A patient with cancer reflects on participating in a clinical study and how community and creativity helped ease chemo brain symptoms.

FDA accepted a new drug application for tirabrutinib in relapsed or refractory PCNSL.